Free Trial

Corvus Pharmaceuticals (CRVS) News Today

Corvus Pharmaceuticals logo
$3.67 +0.18 (+5.16%)
Closing price 04:00 PM Eastern
Extended Trading
$3.59 -0.08 (-2.07%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRVS Latest News

Corvus Pharmaceuticals, Inc. stock logo
OMERS ADMINISTRATION Corp Makes New Investment in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
OMERS ADMINISTRATION Corp purchased a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 75,500 shares of the company's stock, valued at approxi
Corvus Pharmaceuticals, Inc. stock logo
Point72 Asset Management L.P. Sells 2,532,718 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
Point72 Asset Management L.P. lessened its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 45.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,030,011 shares of the company's stock after selling 2,532,
Corvus Pharmaceuticals, Inc. stock logo
Sphera Funds Management LTD. Acquires New Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
Sphera Funds Management LTD. purchased a new position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 500,491 shares of the company's stock, valued at approximately $2,678,000. Sphera Funds
Corvus Pharmaceuticals, Inc. stock logo
RTW Investments LP Invests $14.34 Million in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
RTW Investments LP acquired a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,679,479 shares of
Corvus Pharmaceuticals, Inc. stock logo
Bridgeway Capital Management LLC Has $221,000 Stock Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
Bridgeway Capital Management LLC trimmed its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 67.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,300 sha
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals (NASDAQ:CRVS) Raised to "Hold" at StockNews.com
StockNews.com raised Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Monday.
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Sold by Schonfeld Strategic Advisors LLC
Schonfeld Strategic Advisors LLC trimmed its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 61.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 129,076 shares of the company's stock after sellin
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Bought by Barclays PLC
Barclays PLC raised its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 10,601,800.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 106,019 shares of
Corvus Pharmaceuticals, Inc. stock logo
Deerfield Management Company L.P. Series C Invests $5.35 Million in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
Deerfield Management Company L.P. Series C acquired a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,000,000 shares of the company's
Corvus Pharmaceuticals, Inc. stock logo
Raymond James Financial Inc. Invests $583,000 in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
Raymond James Financial Inc. purchased a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 108,989 shares of the company's stock, valued at approximately $583,000. Raymond
Corvus Pharmaceuticals, Inc. stock logo
74,307 Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Acquired by Acuta Capital Partners LLC
Acuta Capital Partners LLC purchased a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 74,307 shares of the company's stock, valued at approximately $398,000. Acuta Ca
Corvus Pharmaceuticals, Inc. stock logo
Foresite Capital Management VI LLC Buys New Stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
Foresite Capital Management VI LLC bought a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 1,581,233 shares of the company's stock, valued at approximately $8,460,000. Corvus Pharmace
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals (CRVS) Expected to Announce Earnings on Monday
Corvus Pharmaceuticals (NASDAQ:CRVS) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-corvus-pharmaceuticals-inc-stock/)
Corvus Pharmaceuticals, Inc. stock logo
Vivo Capital LLC Has $11.96 Million Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
Vivo Capital LLC raised its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 49.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,234,566 shares of the company's stock a
Corvus Pharmaceuticals, Inc. stock logo
Raymond James Financial Inc. Makes New Investment in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
Raymond James Financial Inc. purchased a new stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 108,989 shares of the company's stock, valued at app
Corvus Pharmaceuticals, Inc. stock logo
HC Wainwright Has Optimistic View of CRVS FY2025 Earnings
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Equities research analysts at HC Wainwright upped their FY2025 earnings per share estimates for Corvus Pharmaceuticals in a report issued on Wednesday, March 26th. HC Wainwright analyst S. Lee now forecasts that the company will earn ($0.
Corvus Pharmaceuticals: Now At Cruising Altitude
Corvus Pharmaceuticals, Inc. stock logo
HC Wainwright Issues Pessimistic Forecast for CRVS Earnings
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at HC Wainwright dropped their FY2028 earnings estimates for Corvus Pharmaceuticals in a research report issued on Wednesday, March 26th. HC Wainwright analyst S. Lee now expects that the company will post earnings per s
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals (NASDAQ:CRVS) Receives Buy Rating from HC Wainwright
HC Wainwright restated a "buy" rating and set a $11.00 price objective on shares of Corvus Pharmaceuticals in a research note on Wednesday.
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals (NASDAQ:CRVS) Issues Quarterly Earnings Results
Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.06).
Corvus Pharmaceuticals reports Q4 EPS (18c), consensus (12c)
Corvus Pharmaceuticals, Inc. stock logo
EntryPoint Capital LLC Purchases New Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
EntryPoint Capital LLC purchased a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 116,645 shares of the company's stock,
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Buy" from Analysts
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) has received a consensus recommendation of "Buy" from the five analysts that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation
Get Corvus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

CRVS Media Mentions By Week

CRVS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRVS
News Sentiment

0.55

1.03

Average
Medical
News Sentiment

CRVS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRVS Articles
This Week

4

2

CRVS Articles
Average Week

Get Corvus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CRVS) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners